Compare ADMA Biologics Inc (ADMA) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs NextEra Energy, Inc. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while NextEra Energy, Inc. trades at $88.32 (market cap $184.51B). The key difference: NextEra Energy, Inc. is far larger — about 86.6× ADMA Biologics Inc's market cap, and NextEra Energy, Inc. pays a 2.82% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NEE | |
|---|---|---|
Market Cap | $2.13B | $184.51B |
Sector | Health | Utilities |
52-Week High | $20.38 | $97.88 |
52-Week Low | $7.60 | $69.77 |
Enterprise Value | $2.20B | $286.92B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NextEra Energy (NEE) trades at $88.47, up 0.15% today, with a neutral technical outlook and strong analyst support. The stock shows solid fundamentals with a P/E of 22.19, net income margin of 29.37%, and recent earnings beats in Q1 2026. Revenue grew to $27.41B in 2025, though net income dipped slightly to $6.84B. A recent $0.62 dividend underscores shareholder returns, while the Dominion Energy merger positions NEE for AI-driven power demand growth.
Outlook remains positive with a consensus price target of $104.29 (18% upside), driven by clean energy demand and partnerships. Risks include rising debt-to-asset ratios (47.6% in 2025) and regulatory pressures. Institutional sentiment is bullish with 66.7% buy ratings, but investors should monitor execution on capital expenditures and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
